{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-030579","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.261195+00:00","generated_at":"2026-05-16T06:02:09.570882+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ALX Oncology prices ~$150M equity offering at $1.57/share; includes pre-funded warrants","bullets":["Gross proceeds expected ~$150M from sale of 76,979,112 common shares at $1.57 and pre-funded warrants for 18,574,120 shares at $1.569.","Offering led by new investors RA Capital Management and TCGX, with participation from existing investors.","Net proceeds to fund evorpacept and ALX2004 clinical trials, working capital.","Expected close on or about Feb 2, 2026, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-030579","json":"https://secwatch.observer/filing/0001193125-26-030579.json","markdown":"https://secwatch.observer/filing/0001193125-26-030579.md","text":"https://secwatch.observer/filing/0001193125-26-030579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/0001193125-26-030579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/d12882d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:02:09.570882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2384bee2b6c4db19aad636669ffd77226b88581","claim":"ALX ONCOLOGY HOLDINGS INC entered into Underwriting Agreement with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters valued at approximately $150 million (effective 2026-01-30).","evidence_excerpt":"On January 30, 2026, ALX Oncology Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 76,979,112 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $1.57 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 18,574,120 shares of Common Stock at an offering price of $1.569 per Pre-Funded Warrant.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/0001193125-26-030579-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters"},{"label":"Value","value":"approximately $150 million"},{"label":"Effective","value":"2026-01-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}